120 related articles for article (PubMed ID: 25443747)
1. L-1416, a novel MDR reversing agent with possible reduced calcium antagonism.
Zhou Z; Tang X; Zhang Y; Hu Z; Wu J; Hu Y
Pharmacol Rep; 2014 Dec; 66(6):1140-7. PubMed ID: 25443747
[TBL] [Abstract][Full Text] [Related]
2. Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416.
Xu Y; Zhi F; Xu G; Tang X; Lu S; Wu J; Hu Y
Biosci Rep; 2012 Dec; 32(6):559-66. PubMed ID: 22757751
[TBL] [Abstract][Full Text] [Related]
3. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K
Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255
[TBL] [Abstract][Full Text] [Related]
4. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
6. HZ08 reverse P-glycoprotein mediated multidrug resistance in vitro and in vivo.
Hu Z; Zhou Z; Hu Y; Wu J; Li Y; Huang W
PLoS One; 2015; 10(2):e0116886. PubMed ID: 25689592
[TBL] [Abstract][Full Text] [Related]
7. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport.
Shirasaka Y; Kawasaki M; Sakane T; Omatsu H; Moriya Y; Nakamura T; Sakaeda T; Okumura K; Langguth P; Yamashita S
Drug Metab Pharmacokinet; 2006 Oct; 21(5):414-23. PubMed ID: 17072095
[TBL] [Abstract][Full Text] [Related]
8. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.
Garrigos M; Mir LM; Orlowski S
Eur J Biochem; 1997 Mar; 244(2):664-73. PubMed ID: 9119038
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.
Farrell RJ; Menconi MJ; Keates AC; Kelly CP
Aliment Pharmacol Ther; 2002 May; 16(5):1021-31. PubMed ID: 11966513
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells.
Wang FP; Wang L; Yang JS; Nomura M; Miyamoto K
Biol Pharm Bull; 2005 Oct; 28(10):1979-82. PubMed ID: 16204959
[TBL] [Abstract][Full Text] [Related]
12. [Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma].
Okano M; Kawamoto S; Nezasa S; Tamaki M; Ehara H; Yamada S; Deguchi T; Kawada Y
Nihon Hinyokika Gakkai Zasshi; 1996 Aug; 87(8):1041-7. PubMed ID: 8831211
[TBL] [Abstract][Full Text] [Related]
13. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
14. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
15. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
16. Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro.
Eliason JF; Ramuz H; Yoshikubo T; Ishikawa T; Yamamoto T; Tsuruo T
Biochem Pharmacol; 1995 Jul; 50(2):187-96. PubMed ID: 7632162
[TBL] [Abstract][Full Text] [Related]
17. A novel bioassay for P-glycoprotein functionality using cytochalasin D.
Elbling L; Berger W; Weiss RM; Printz D; Fritsch G; Micksche M
Cytometry; 1998 Mar; 31(3):187-98. PubMed ID: 9515718
[TBL] [Abstract][Full Text] [Related]
18. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.
Shiraki N; Hamada A; Ohmura T; Tokunaga J; Oyama N; Nakano M
Biol Pharm Bull; 2001 May; 24(5):555-7. PubMed ID: 11379779
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
20. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
